EU releases guidance for medicine shortages
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
List view / Grid view
News
NICE endorses dacomitinib for treatment of lung cancer
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
US government takes steps to reduce drug costs
New regulations and legislations are being formed in the US to combat healthcare costs, including drug prices.
£3 million for no-deal Brexit medication transport
The DHSC has announced their plans for pharmaceutical transportation in the case of a no-deal Brexit.
Drugs-on-a-coil method could free patients from the burden of taking pills
A research group has designed a pills-on-a-coil system to administer drugs without having to take pills.
Decision by NICE for the use of osimertinib to be appealed
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
FDA approves treatment for refractory multiple myeloma
Accelerated approval has been granted to Xpovio to treat refractory multiple myeloma by the FDA.
Phase III programme for the use of otilimab for rheumatoid arthritis launched
A Phase III clinical development programme testing otilimab in patients with RA has begun.
Crystallised drug formulation extends medical device function
A study has shown that crystallising drugs removes localised immune reaction, allowing long-term release of drugs from medical devices.
FDA releases guidance on pharmaceutical product labelling
New guidance drafts have been announced by the FDA to improve patients understanding and keep information consistent.
The Chief Executive of ABPI has announced his retirement
ABPI Chief Executive, Mike Thompson, will retire at the end of 2019.
Clinical trial sponsors called to publish results on EU database
All sponsors of clinical trials conducted in the European Union have been reminded of their obligation to make summaries of trial results.
Global pharmaceutical filler market set to increase 5.7 percent
The filler market is predicted to increase to US$2 billion by 2024, according to a new report.
FDA issues three warning letters to API re-packers
Three API re-packers who failed to meet current good manufacturing practice requirements have received warning letters from the FDA.
Report suggests process for vaccine trials during health crises
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.
